Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

Trial statusRecruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexMale

Age8-45

SponsorFrontera Therapeutics

About this trial

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

None

None

18 Participants

are divided into 3 treatment groups

Frontera Therapeutics

Lead sponsor

Eye & ENT Hospital of Fudan University

Collaborator

Peking Union Medical College Hospital

Collaborator

Henan Provincial People's Hospital

Collaborator